Compare OVBC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | IMUX |
|---|---|---|
| Founded | 1872 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 209.2M |
| IPO Year | 1996 | 2013 |
| Metric | OVBC | IMUX |
|---|---|---|
| Price | $46.86 | $13.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 26.9K | ★ 196.4K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | 38.00 |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $0.51 |
| 52 Week High | $51.25 | $17.43 |
| Indicator | OVBC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 28.95 |
| Support Level | $46.54 | $11.21 |
| Resistance Level | $47.12 | $15.82 |
| Average True Range (ATR) | 1.17 | 1.17 |
| MACD | 0.18 | -0.43 |
| Stochastic Oscillator | 84.96 | 7.58 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.